On Monday, Shares of Crocs, Inc. (NASDAQ:CROX), gained 4.33% to $13.49.
Crocs, declared that it will host a conference call to talk about the results of its first quarter ended March 31, 2015 on Friday, May 8, 2015 at 8:30 a.m. EDT. The call participation number is (888) 771-4371. A replay of the conference call will be accessible two hours after the completion of the call at (888) 843-7419. International participants can dial (847) 585-4405 to take part in the conference call and can access a replay of the call at (630) 652-3042.
Crocs, Inc. designs, develops, manufactures, markets, and distributes casual lifestyle footwear, apparel, and accessories for men, women, and children worldwide. The company designs and sells a range of footwear and accessories that utilize its proprietary closed cell-resin, called Croslite.
At the end of Monday’s trade, Shares of iBio, Inc. (NYSEMKT:IBIO), jumped 4.29% to $0.94.
iBio, declared the issue of a new U.S. patent expanding the company’s iBioModulator™ thermostable immunomodulator protein portfolio. The new patent, serial number 9,012,199, is entitled “Recombinant Carrier Molecule for Expression, Delivery, and Purification of Target Polypeptides.” The fundamental composition of matter claims grant iBio important exclusivity over new, modified carrier molecules derived from the company’s proprietary iBioModulator™ thermostable immunomodulator protein system and their use with one or more target proteins or antigens.
The commercial significance of these proprietary carriers is that they enable creation of high-performance vaccine candidates for difficult disease targets. The iBioModulator™ thermostable immunomodulator protein platform has been shown to significantly improve the immune response to a vaccine in two important ways. It enhances the strength of the initial immune response to a vaccine antigen (as measured by antibody titer) and extends the duration of the immune response. Generating a stronger immune response and prolonged immunity without booster inoculations adds noteworthy value to a vaccine by reducing the overall costs and logistical difficulties of its use. These improvements may also enable a government or commercial producer to achieve and maintain protection of more of a vaccine’s target population.
The iBioModulator™ thermostable immunomodulator protein platform, counting the technology covered by this new patent, is applicable to biopharmaceutical products developed with iBio’s proprietary iBioLaunch™ plant-based gene expression system and can also be used with other protein expression systems. iBio offers the benefits of its technology through licenses and also offers technology transfer arrangements for clients interested in fully autonomous manufacturing capabilities.
The new patent joins iBio’s other patents in this family in the US (8,173,408, 8,591,909), and also patents in international markets of interest to iBio and its clients, counting Australia, Canada, China, India, Germany, France, Ireland, Italy, Spain and United Kingdom. Patents covering the iBioModulator™ thermostable immunomodulator protein platform are directly related to that part of iBio’s larger portfolio of intellectual property relevant to the development and manufacture of vaccines for a range of infectious diseases counting plague, anthrax, human papilloma virus, and influenza. This immunomodulator portfolio comprises vaccine product patents in the US (8,124,103, 8,277,816, 8,404,252, 8,945,580) and internationally.
iBio, Inc., a biotechnology company, focuses on the commercialization of its proprietary plant-based protein expression technologies in the United States and internationally. Its proprietary technologies comprise iBioLaunch, a transformative platform technology for the development and production of therapeutic proteins and vaccines; and iBioModulator, a technology platform that enhances the potency and duration of the effect of prophylactic and therapeutic vaccines.
Key Energy Services Inc. (NYSE:KEG), ended its last trade with 4.18% gain, and closed at $2.49.
Key Energy Services, stated first quarter 2015 merged revenues of $267.8 million and a pre-tax GAAP loss of $91.1 million, or $0.39 per share. The results for the first quarter comprise:
- a pre-tax charge of $21.7 million, or $0.09 per share, for a true-up to the impairment charge recorded in the fourth quarter 2014 associated with the Coiled Tubing Services segment;
- pre-tax costs of $18.0 million, or $0.08 per share, related to the formerly revealed Foreign Corrupt Practices Act (“FCPA”) investigations;
- a pre-tax charge of $4.0 million, or $0.02 per share, for a reserve associated with the receivable from the Company’s 2012 sale of its’ Argentine business;
- pre-tax costs of $3.3 million, or $0.01 per share, due to severance; and
- a pre-tax charge of $2.2 million, or $0.01 per share, related to assets destroyed in Mexico.
Key Energy Services, Inc. operates as an onshore rig-based well servicing contractor in the United States and internationally. It offers rig-based services, counting the maintenance, workover, and recompletion of existing oil wells; completion of newly-drilled wells; and plugging and abandonment of wells at the end of their lives, in addition to specialty drilling services to oil and natural gas producers.
Finally, Coeur Mining, Inc. (NYSE:CDE), closed at $5.45, with 4.01% gain.
Coeur Mining, stated first quarter 2015 revenue of $153.0 million, adjusted EBITDA 1 of $21.7 million, and adjusted net loss of $0.24 per share. Adjusted all-in sustaining costs declined 8% from the fourth quarter of 2014 to $17.66 per silver equivalent ounce, the lowest level in the two years of reporting this metric. Adjusted costs applicable to sales per silver equivalent ounce 1 of $13.71 declined 5% from the fourth quarter.
First Quarter 2015 Highlights
- Silver production was 3.8 million ounces and gold production was 69,734 ounces, or 8.0 million silver equivalent ounces as formerly declared on April 6, 2015
- Adjusted all-in sustaining costs were $17.66 per silver equivalent ounce, down 8% from the fourth quarter
- Adjusted costs applicable to sales per silver equivalent ounce were $13.71, a 5% decrease from the fourth quarter and the lowest level in a year
- Adjusted costs applicable to sales per gold ounce at Kensington were $797, almost unchanged from the fourth quarter
- Adjusted costs applicable to sales per silver equivalent ounce at Palmarejo dropped 7% from the fourth quarter to $14.56
- Adjusted costs applicable to sales per silver equivalent ounce at Rochester were $12.95, down 6% from the fourth quarter
- Attained the Wharf gold mine from a partner of Goldcorp for $103 million in cash
- Cash, cash equivalents, and short-term investments were $179.6 million at March 31, 2015
- Shares issued and outstanding were 136.0 million as of May 1, 2015.
Coeur Mining, Inc., through its auxiliaries, engages in the ownership, operation, exploration, and development of silver and gold mining properties primarily in the United States, Mexico, Bolivia, Argentina, Australia, Ecuador, Chile, and New Zealand.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
